Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Digital Health – The Next Gold Rush Of Opportunities, Says Kaiser Permanente Ventures

Executive Summary

Digital health is no longer a buzzword but a reality, with venture capital investment in this space reaching an all-time high. This Q&A with Jordan Kramer of Kaiser Permanente Ventures provides insight into why digital health investment has rocketed, how Kaiser Permanente's approach to investing in this sector, and where the opportunities and challenges lie for digital health start-ups.

You may also be interested in...

The Benevolent Investor: Institutional Ventures Grow In Size And Reach

A growing number of medical research institutions are investing in start-ups as a venture capitalist would, at times in new companies that have only tangential ties to the home institution.

Versant Continues “Build-To-Buy” With New Fund

Versant Ventures joined the ranks of venture capital firms closing new funds recently, thanks in part to the swell in biotech initial public offerings this year. Versant’s Fund V represents an oversubscribed level of approximately $55 million to its intended $250 million target.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts